Fig. 1From: Prognostic value of an automated bone scan index for men with metastatic castration-resistant prostate cancer treated with cabazitaxelKaplan–Meier curve of overall survival (OS) after administration of cabazitaxel. The median OS after cabazitaxel was 10.0 months (95% confidence interval [CI], 7.8–12.2 months)Back to article page